CeNeS licenses promising sedative to Ono

Japan's Ono Pharmaceuticals has licensed the Japanese rights to CeNeS' short active sedative CNS-7056 for an undisclosed amount of money and milestones. CeNeS has touted the drug's performance in preclinical studies, noting its swift action and the swift disappearance of sedation after dosing. The UK's CeNeS recently announced a 6 million pound private placement to pay for late-stage studies of its painkiller M6G, which is designed to replace morphine. That deal was touted as a move to better position CeNeS for new acquisitions and new licensing pacts like the one announced today.

- here's the release on the licensing agreement
- check out this background on CeNes

Related Articles:
Locus and Ono ink drug discovery pact. Report
Ono halts US trials on acute stroke drug. Report

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.